Signos, the company behind the first FDA-cleared over-the-counter continuous glucose monitoring (CGM) system designed for weight management, announced a $20 million funding round backed by GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama. The funding is expected to support the company’s next phase of growth as demand increases for personalized metabolic health and weight management tools.
As part of the investment, Signos and Dexcom are expanding their partnership, with the Signos system becoming available for purchase through Dexcom’s direct-to-consumer platform, Stelo.com. The collaboration is designed to make the company’s weight management solution more accessible to consumers seeking data-driven approaches to improving metabolic health.
Founded in 2018, Signos has developed an AI-powered platform that combines glucose data from Dexcom’s Stelo glucose biosensor with personalized health analytics. The platform analyzes data related to meals, activity, and other lifestyle factors, providing users with insights into how their bodies respond to different behaviors and helping them make adjustments aligned with their health goals.
According to the company, growth has accelerated significantly, with Signos reporting a tenfold increase in growth over the past six months. The company attributes this momentum to increasing interest in personalized health technologies and the broader adoption of GLP-1 medications for weight management.
At the core of the platform is Signos’ proprietary behavioral AI engine, which evaluates health data and generates personalized feedback based on an individual’s metabolic responses. The system is designed to help users understand how specific foods, meals, and daily habits influence glucose levels and long-term weight management outcomes.
The company believes this approach can play an important role for individuals using GLP-1 medications by providing deeper metabolic insights that extend beyond appetite suppression. Signos positions its platform as a tool that can help users build sustainable habits and maintain long-term results through a better understanding of their own biology.
Dexcom’s participation in the financing reflects growing interest in expanding glucose biosensing applications beyond traditional diabetes management. Through the partnership, Dexcom’s Stelo biosensor serves as the foundation of the Signos system, enabling users to access real-time glucose information and personalized recommendations.
The financing round also included participation from Blue Cross Blue Shield of Alabama through 450 Ventures. The investment represents growing interest among healthcare payers in preventive metabolic health solutions, particularly as insurers evaluate ways to improve outcomes while managing the rising costs associated with obesity treatment and GLP-1 medications.
Signos said its mission is to help eliminate obesity by advancing the metabolic health movement through personalized data, AI-powered insights, and accessible glucose monitoring technology.
KEY QUOTES:
“The weight management category is being completely reimagined right now, and the approaches that will endure are the ones that combine the best of medication with the best of personalized data. Signos provides the scoring of every meal with AI, delivering a daily weight loss signal, and giving people the kind of real biological insight that helps users make their results last.”
Sharam Fouladgar-Mercer, CEO And Founder, Signos
“Signos has developed a system that translates glucose biosensing data into actionable insights for people focused on weight management. Making Signos available on Stelo.com is a natural next step. It makes a powerful, FDA-cleared technology even more accessible for people who are already looking for smarter ways to manage their weight and health.”
Jon Coleman, Chief Commercial Officer, Dexcom
